Thiazolidinediones are associated with a reduced risk of COPD exacerbations

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 1591-1597

  Rinne, Seppo T ^a,b   Liu, Chuan Fen ^c,d   Feemster, Laura C ^c,d   Collins, Bridget F ^c,d   Bryson, Christopher L ^c,e   O’Riordan, Thomas G ^f   Au, David H ^c,d  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f GILEAD SCIENCES INC   (United States)

Author keywords

Cohort study; COPD exacerbation; Glitazones; Inflammation; Peroxisome proliferator activated receptors

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLITAZONE DERIVATIVE; IPRATROPIUM BROMIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TIOTROPIUM BROMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EXPOSURE; FEMALE; HOSPITAL PATIENT; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PRESCRIPTION; REGRESSION ANALYSIS; RISK REDUCTION; VETERAN; COMORBIDITY; DISEASE COURSE; GOVERNMENT; INCIDENCE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; ORAL DRUG ADMINISTRATION; PROTECTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES; VETERANS HEALTH;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; COMORBIDITY; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROTECTIVE FACTORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS HEALTH;

EID: 84939232192     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S82643     Document Type: Article

References (37)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, preva­lence, and future trends. Lancet. 2007;370(9589):765–773.
2. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep. 2011;59(10):1–126.
3. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412.
4. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD. 2006;3(4):211–218.
5. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The eco­nomic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7(3):214–228.
6. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerba­tions of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(3):245–251.
7. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagno­sis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.
8. Aaron SD, Vandemheen KL, Fergusson D, et al; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotro­pium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–555.
9. Remels AH, Gosker HR, Schrauwen P, Langen RC, Schols AM. Peroxi­some proliferator-activated receptors: a therapeutic target in COPD? Eur Respir J. 2008;31(3):502–508.
10. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidin­edione receptor. Diabetes. 1998;47(4):507–514.
11. Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy. 2006;36(12):1494–1504.
12. Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol. 2003;170(5):2663–2669.
13. Rinne ST, Feemster LC, Collins BF, et al. Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study. Allergy Asthma Clin Immunol. 2014;10(1):34.
14. Cooke CR, Joo MJ, Anderson SM, et al. The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. BMC Health Serv Res. 2011;11:37.
15. Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo). 2011;2011:861926.
16. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epide­miol. 2008;167(4):492–499.
17. Joish VN, Malone DC, Wendel C, Draugalis JR, Mohler MJ. Devel­opment and validation of a diabetes mellitus severity index: a risk-adjustment tool for predicting health care resource use and costs. Pharmacotherapy. 2005;25(5):676–684.
18. Ash AS, Ellis RP, Pope GC, et al. Using diagnoses to describe popula­tions and predict costs. Health Care Financ Rev. 2000;21(3):7–28.
19. Dendale P, De Keulenaer G, Troisfontaines P, et al. Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) study. Eur J Heart Fail. 2012;14(3):333–340.
20. StataCorp. Stata Statistical Software: Release 11.2. College Station, TX: StataCorp LP; 2012.
21. Bryson CL, Au DH, Young B, McDonell MB, Fihn SD. A refill adher­ence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care. 2007;45(6):497–504.
22. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary man­agement of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290(17):2301–2312.
23. Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized beclometha­sone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis. 1992;146(2):389–395.
24. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest. 2010;137(2):318–325.
25. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240(4854):889–895.
26. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Per­oxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol. 2003;85(2–5):267–273.
27. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137(1):354–366.
28. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–86.
29. Wang AC, Dai X, Luu B, Conrad DJ. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol. 2001;24(6):688–693.
30. Zhu M, Flynt L, Ghosh S, et al. Anti-inflammatory effects of thiazo­lidinediones in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 2011;45(1):111–119.
31. Richards DB, Bareille P, Lindo EL, Quinn D, Farrow SN. Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial. Respir Med. 2010;104(5):668–674.
32. Spears M, Donnelly I, Jolly L, et al. Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther. 2009;86(1):49–53.
33. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One. 2012;7(8):e43892.
34. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11(8):861–866.
35. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108(23):2941–2948.
36. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocar­dial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
37. Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(12):1301–1306.